학술논문
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
non-small-cell lung cancer
Original Article
non-small-cell lung cancer
Original Article
Document Type
Clinical report
Author
Herbst, Roy S.; Giacone, Giuseppe; Marinis, Filippo de; Reinmuth, Niels; Vergnenegre, Alain; Barrios, Carlos H.; Morise, Masahiro; Felip, Enriqueta; Andric, Zoran; Geater, Sarayut; Ozguroglu, Mustafa; Zou, Wei; Sandler, Alan; Enquist, Ida; Komatsubara, Kimberly; Deng, Yu; Kuriki, Hiroshi; Wen, Xiaohui; McCleland, Mark; Mocci, Simonetta; Jassem, Jacek; Spigel, David R.
Source
The New England Journal of Medicine. Oct 1, 2020, Vol. 383 Issue 14, p1328, 12 p.
Subject
Language
English
ISSN
0028-4793
Abstract
The safety and efficacy of atezolizumab as a first-line treatment for patients with metastatic non-small-cell lung cancer with PD-L1 expression are examined. Ateolizumab resulted in significantly longer overall survival compared to platinum-based chemotherapy.